Exicure Stock (NASDAQ:XCUR)

Forecast Ownership Financials Chart

Previous Close

$0.93

52W Range

$0.88 - $9.48

50D Avg

$1.19

200D Avg

$2.72

Market Cap

$6.61M

Avg Vol (3M)

$45.46K

Beta

3.63

Div Yield

XCUR Company Profile

Exicure, Inc. does not have significant operations. Previously, it focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. The company has a co-development agreement with Adbiotech Co., Ltd. to explore combination therapies based on Burixafor (GPC-100) across multiple therapeutic areas. Exicure, Inc. was founded in 2011 and is headquartered in Redwood City, California.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

May 22, 2018

Website

XCUR Performance

XCUR Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	$500.00K	-
Operating Income	-	$-12.23M	$-15.00M
Net Income	$-4.95M	$-9.70M	$-16.91M
EBITDA	-	$-8.85M	$-15.54M
Basic EPS	$-0.79	$-1.59	$-2.11
Diluted EPS	$-0.79	$-1.59	$-2.11

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
RLYB	Rallybio Corporation
CLGN	CollPlant Biotechnologies Ltd.
NRSN	NeuroSense Therapeutics Ltd.
CVKD	Cadrenal Therapeutics, Inc. Common Stock
MTVA	MetaVia Inc.
TAOX	TAO Synergies Inc.
IBIO	iBio, Inc.
KLTO	Klotho Neurosciences, Inc.
SONN	Sonnet BioTherapeutics Holdings, Inc.